FDA approves skin cancer vaccine by...?

According to the latest prediction market data for the query “FDA approves skin cancer vaccine by...?”, traders have formed a strong consensus.

Currently, December 31, 2027 is dominating the market with an overwhelming 60.5% chance of winning. June 30, 2027 follows in second place at 28.5%. The betting volume for this specific market has already reached $96.5K, reflecting intense industry interest.

To better assess where each potential outcome stands, the market can be segmented into three distinct trading tiers based on implied probability and contract pricing:

🥇 Tier 1: The Dominant Leader

• December 31, 2027 (60.5%): Currently commanding the highest probability, December 31, 2027 is heavily favored by the order book. Traders looking to back this outcome face a “Buy Yes” contract price of 61¢, signaling a high degree of market conviction. This contract alone has generated $82.3K in volume.

🥈 Tier 2: The Primary Challengers

• June 30, 2027 (28.5%): Positioned as the most viable alternative, June 30, 2027 maintains a 28.5% chance of resolving true. Its “Buy Yes” shares currently trade at 28¢.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".

Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.

Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above. Approval as part of a combination regimen will qualify. Approval for a narrower population than the one studied in INTerpath-001 will qualify. Approval for an indication other than melanoma will also qualify. Both standard and accelerated approval will qualify.

An approval is defined as:

For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)

For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced

For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)

For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:

Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:

Approvable letters that require additional actions before approval

Tentative approvals pending patent or exclusivity expiration

FDA requests for additional information or studies

Extension of Prescription Drug User Fee Act (PDUFA) dates

Approval for compassionate use or expanded access programs only

Approval only for export or for use outside the United States

Emergency Use Authorization (EUA) without full approval

Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source for this market will be official information from the FDA; however, a consensus of credible reporting may also be used.

While human consensus and speculative volume shape the broader prediction market, our quantitative algorithms offer a data-driven counter-perspective. By analyzing fundamental signals, underlying trends and historical distributions, our AI Valuation model calculates an independent “Fair Value” probability for each outcome.

Comparing this Fair Value against the current Trade Value uncovers major disparities — known as the Expected Value (EV) Gap. Contracts with a positive EV Gap represent statistically underpriced outcomes, whereas a negative EV Gap flags a potential market overreaction.

Top AI Alpha & Mispriced Arbitrage Opportunities

Based on the latest data model run, several key contracts stand out with significant deviations:

• The Most Overvalued Outcome June 30, 2027 currently trades at 28.5%, but our AI places its Fair Value at just 17.8%. This creates a large negative EV Gap of -10.7%, suggesting the crowd may be overhyping this outcome and driving the premium too high.
• The Best Value Play (Highest EV) Our model identifies December 31, 2027 as the premium value opportunity on the board. While the market only assigns it a 60.5% trading probability, our AI’s Fair Value assessment sits at 67% — yielding an impressive +6.5% EV Gap.